中国临床药理学杂志2023，Vol.39Issue(23)：3393-3396,4.DOI:10.13699/j.cnki.1001-6821.2023.23.011
马来酸麦角新碱和缩宫素促进产后子宫复旧的临床研究
Clinical trial of ergometrine maleate combined with oxytocin in promoting postpartum uterine involution
摘要
Abstract
Objective To compare the clinical efficacy and safety of ergometrine maleate combined with oxytocin and oxytocin alone in the treatment of uterine involution and prevention of secondary postpartum bleeding.Methods The parturients who delivered through vaginal delivery without complications were divided into treatment and control groups.In the treatment group,oxytocin 20 U was intravenously given and ergometrine maleate 0.2 mg was intramuscularly given immediately after the third stage of labor;followed by intramuscular injection of ergometrine maleate 0.2 mg 2 hours after delivery and intramuscular injection of ergometrine maleate 0.2 mg 24 h after delivery.The control group immediately received intravenous infusion of oxytocin 20 U after placenta delivery in the third stage of labor,followed by intramuscular injection of oxytocin 20 U 2 hours postpartum and intravenous infusion of oxytocin 20 U 24 hours postpartum.The amount of postpartum lochia,the duration of lochia and the occurrence of adverse drug reaction were compared between two groups.Results A total of 226 patients were included,including 95 cases in the treatment group and 131 cases in the control group.Lochia volumes at 2 to 24 h and 24 to 48 h postpartum in the treatment group were(65.11±45.18)and(31.73±17.80)mL,significantly lower than those of control group[(109.33±75.97)and(56.01±33.81)mL];the duration was significantly shorter than that of control group[(10.48±7.71)vs(12.47±7.76)min],and the differences were statistically significant(all P＜0.05).At the time of discharge,the uterine volumes of treatment and control groups were(265.17±204.65)and(319.17±214.57)mm3,and the difference was statistically significant(P＜0.05).In both groups,adverse drug reactions were observed after the application of uterine contraction agent,mainly including hypertension,headache,nausea and vomiting.The incidences of adverse drug reaction in the treatment group and the control group were 0.10％and 0.70％,which were similar.Conclusion Both methods can promote uterine involution of parturient women.Compared with oxytocin,the combination of ergometrine maleate and oxytocin has no obvious advantage in reducing adverse drug reaction,but it has certain advantages in promoting uterine contraction and promoting uterine involution.关键词
马来酸麦角新碱注射液/缩宫素注射液/子宫复旧/产后出血/临床疗效/安全性评价Key words
ergometrine maleate injection/oxytocin injection/uterine involution/postpartum hemorrhage/clinical efficacy/safety evaluation分类
医药卫生引用本文复制引用
陈佳,罗欣,李飞霏,杨晓畅..马来酸麦角新碱和缩宫素促进产后子宫复旧的临床研究[J].中国临床药理学杂志,2023,39(23):3393-3396,4.基金项目
重庆医科大学附属第一医院学科提升工程"学科创新基金"学科培育基金资助项目(xkts117) （xkts117）
